FATE THERAPEUTICS INC (FATE) Stock Price, Quote, News and Overview
NASDAQ:FATE - Nasdaq - US31189P1021 - Common Stock - Currency: USD
FATE Quote, Performance and Key Statistics
1.42
-0.12 (-8.09%)
The current stock price of FATE is 1.42 USD. In the past month the price increased by 5.97%. In the past year, price decreased by -79.6%.
FATE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About FATE
Company Profile
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 181 full-time employees. The company went IPO on 2013-10-01. The firm is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Company Info
FATE THERAPEUTICS INC
12278 Scripps Summit Drive
San Diego CALIFORNIA 92121 US
CEO: J. Scott Wolchko
Employees: 181
Company Website: https://fatetherapeutics.com/
Investor Relations: https://ir.fatetherapeutics.com/
Phone: 18588751803
FATE THERAPEUTICS INC / FATE FAQ
What is the stock price of FATE THERAPEUTICS INC today?
The current stock price of FATE is 1.42 USD. The price decreased by -8.09% in the last trading session.
What is the ticker symbol for FATE THERAPEUTICS INC stock?
The exchange symbol of FATE THERAPEUTICS INC is FATE and it is listed on the Nasdaq exchange.
On which exchange is FATE stock listed?
FATE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FATE THERAPEUTICS INC stock?
24 analysts have analysed FATE and the average price target is 6.46 USD. This implies a price increase of 354.93% is expected in the next year compared to the current price of 1.42. Check the FATE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FATE THERAPEUTICS INC worth?
FATE THERAPEUTICS INC (FATE) has a market capitalization of 161.72M USD. This makes FATE a Micro Cap stock.
How many employees does FATE THERAPEUTICS INC have?
FATE THERAPEUTICS INC (FATE) currently has 181 employees.
What are the support and resistance levels for FATE THERAPEUTICS INC (FATE) stock?
FATE THERAPEUTICS INC (FATE) has a resistance level at 1.43. Check the full technical report for a detailed analysis of FATE support and resistance levels.
Is FATE THERAPEUTICS INC (FATE) expected to grow?
The Revenue of FATE THERAPEUTICS INC (FATE) is expected to decline by -78.85% in the next year. Check the estimates tab for more information on the FATE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy FATE THERAPEUTICS INC (FATE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FATE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FATE, evaluating the profitability, health, valuation and growth aspects
- FATE THERAPEUTICS INC (FATE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FATE THERAPEUTICS INC (FATE) Sales and EPS estimates to see what analysts future expectations are.
- FATE THERAPEUTICS INC (FATE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FATE THERAPEUTICS INC (FATE) Insider and Institutional Ownership to learn about the owners and their transactions.
- FATE THERAPEUTICS INC (FATE) Stock Chart to make your own analysis
- FATE THERAPEUTICS INC (FATE) Latest news and press-releases to stay up to date.
Does FATE THERAPEUTICS INC (FATE) stock pay dividends?
FATE does not pay a dividend.
When does FATE THERAPEUTICS INC (FATE) report earnings?
FATE THERAPEUTICS INC (FATE) will report earnings on 2025-03-03, after the market close.
What is the Price/Earnings (PE) ratio of FATE THERAPEUTICS INC (FATE)?
FATE THERAPEUTICS INC (FATE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.65).
What is the Short Interest ratio of FATE THERAPEUTICS INC (FATE) stock?
The outstanding short interest for FATE THERAPEUTICS INC (FATE) is 11.77% of its float. Check the ownership tab for more information on the FATE short interest.
FATE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FATE. When comparing the yearly performance of all stocks, FATE is a bad performer in the overall market: 97.47% of all stocks are doing better.
FATE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FATE. No worries on liquidiy or solvency for FATE as it has an excellent financial health rating, but there are worries on the profitability.
FATE Financial Highlights
Over the last trailing twelve months FATE reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 6.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.01% | ||
| ROE | -49.19% | ||
| Debt/Equity | 0 |
FATE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to FATE. The Buy consensus is the average rating of analysts ratings from 24 analysts.
For the next year, analysts expect an EPS growth of -1.31% and a revenue growth -78.85% for FATE